Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia

Brief Summary

Official Title: “Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia”

The goal of the present study is to compare the effectiveness of the active (S)-enantiomer of citalopram, escitalopram with placebo in the treatment of patients with depressive syndrome complicating Alzheimer’s dementia (AD), vascular dementia (VD) or mixed dementia (MD), for 8 weeks of double-blind treatment.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Interventions Used in this Clinical Trial

  • Drug: Escitalopram

Outcome Measures for this Clinical Trial

Primary Measures

  • Cornell Scale for Depression in Dementia (CSDD) total score

Secondary Measures

  • Cohen-Mansfield Agitation Inventory (CMAI; Cohen-Mansfield et al. 1989)

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Subject meets criteria for the diagnosis of Alzheimer’s dementia, or vascular dementia, or mixed alzheimer's and vascular dementia, according to Diagnostic and Statistical for Mental Disorders, Fourth Edition (DSM-IV) criteria.
  • Subject meets the following criteria for depressive syndrome: DSM-IV criteria for major depressive episode; and Cornell Scale of Depression in Dementia is 18 or more.
  • The depressive syndrome has been present for at least two weeks preceding study entry (Visit 1).
  • The depressive syndrome must be at least moderate in severity at Visit 1 and Visit 2 (cause the subject impairment in functional capacity) and in the opinion of the investigator require pharmacological intervention.
  • Score on the Mini Mental State Examination (MMSE) of 10-26 at Visit 1 and at Visit 2.
  • Other possible reasons for the subject’s depressive symptoms, for example, medications or other medical conditions (such as pain, infection, cancer of the pancreas, etc.), have been excluded as an etiology.

Exclusion Criteria

General Exclusion Criteria:

  • Subjects who need placebo run-in period, and/or their caregivers are unable to comply with Study Period I medication to the extent that drug compliance in the remainder of the study would be compromised as determined by the investigator.
  • Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.

Diagnostic Exclusion Criteria:

  • Schizophrenia
  • Subjects who are judged clinically to be at serious suicidal risk at Visit 1.
  • Subjects who have clinically significant psychotic symptoms at Visit 1.
  • Subject has a serious neurological condition other than AD, VD or MD including, but not limited to: traumatic (head-brain) dementia, space-occupying lesion, relevant structural abnormalities on brain imaging, etc.
  • Subject who underwent CVA for 3 months.
  • Subject is doing well on a current antidepressant drug regimen.

Exclusionary Concurrent or Historical Illness:

  • Subjects with severe hepatic or renal insufficiency.
  • Hypo/hyperthyroidism
  • B-12 deficiency

Exclusionary Concomitant or Historical Medications:

  • Participation in a clinical trial of another investigational drug within 30 days prior to study entry (Visit 1) and/or any concurrent investigational study.
  • Subjects with a history of severe adverse reaction to citalopram or escitalopram.
  • Concomitant medication as specified.
  • Previous treatment with escitalopram unless, in the opinion of the investigator, the patient’s previous treatment was inadequate in dose and/or duration to provide an accurate assessment of the therapy.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 60 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Sheba Medical Center
  • Collaborator
    • H. Lundbeck A/S
  • Overall Official(s)
    • Anna Sverdlik, MD, Principal Investigator, Sheba Medical Center
  • Overall Contact(s)
    • Anna Sverdlik, MD, 972-54-4718424,


Clinical Trials content is provided directly by the US National Institutes of Health via and is not reviewed separately by Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: